Ontuxizumab  (Synonyms: MORAb-004)

Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

TEM1/Endosialin/CD248

Ontuxizumab (0-100 μg/mL; 12 h) induces CD248 internalization and dose-dependently reduces 46% CD248 of cell surface of human pericytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

57124  [NCBI]

Q9HCU0

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.75 kDa

946415-62-9

Liquid

Colorless to light yellow

[Ontuxizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Endosialin/CD248 Protein, Human (HEK293, His, HY-P78042) can bind Ontuxizumab. The EC₅₀ for this effect is 3.164 ng/mL.

• [1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40.  [Content Brief]